Details

Autor(en) / Beteiligte

• Livanos, Alexandra E.
• Dunn, Alexandra
• Fischer, Jeremy
• Ungaro, Ryan C.
• Turpin, Williams
• Lee, Sun-Ho
• Rui, Shumin
• Del Valle, Diane Marie
• Jougon, Julia J.
• Martinez-Delgado, Gustavo
• Riddle, Mark S.
• Murray, Joseph A.
• Laird, Renee M.
• Torres, Joana
• Agrawal, Manasi
• Magee, Jared S.
• Dervieux, Thierry
• Gnjatic, Sacha
• Sheppard, Dean
• Sands, Bruce E.
• Porter, Chad K.
• Croitoru, Kenneth
• Petralia, Francesca
• Abreu, Maria
• Beck, Paul
• Bernstein, Charles
• Dieleman, Leo
• Feagan, Brian
• Griffiths, Anne
• Guttman, David
• Jacobson, Kevan
• Kaplan, Gilaad
• Krause, Denis O.
• Madsen, Karen
• Marshall, John
• Moayyedi, Paul
• Ropeleski, Mark
• Seidman, Ernest
• Silverberg, Mark
• Snapper, Scott
• Stadnyk, Andy
• Steinhart, Hillary
• Surette, Michael
• Turner, Dan
• Walters, Thomas
• Vallance, Bruce
• Aumais, Guy
• Bitton, Alain
• Cino, Maria
• Critch, Jeff
• Denson, Lee
• Deslandres, Colette
• El-Matary, Wael
• Herfarth, Hans
• Higgins, Peter
• Huynh, Hien
• Hyams, Jeff
• Mack, David
• McGrath, Jerry
• Otley, Anthony
• Panancionne, Remo
• Shapiro, Jason
• Shah, Samir
• Leleiko, Neal S.
• Colombel, Jean-Frederic
• Mehandru, Saurabh

Titel

Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis

Ist Teil von

• Gastroenterology (New York, N.Y. 1943), 2023-04, Vol.164 (4), p.619-629

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin αvβ6 (anti-αvβ6) autoantibodies have been described in patients with UC. We tested for the presence of anti-αvβ6 antibodies in the preclinical phase of UC and studied their association with disease-related outcomes after diagnosis. Anti-αvβ6 autoantibodies were measured in 4 longitudinal serum samples collected from 82 subjects who later developed UC and 82 matched controls from a Department of Defense preclinical cohort (PREDICTS [Proteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects]). In a distinct, external validation cohort (Crohn’s and Colitis Canada Genetic Environmental Microbial project cohort), we tested 12 pre-UC subjects and 49 matched controls. Furthermore, anti-αvβ6 autoantibodies were measured in 2 incident UC cohorts (COMPASS [Comprehensive Care for the Recently Diagnosed IBD Patients], n = 55 and OSCCAR [Ocean State Crohn's and Colitis Area Registry], n = 104) and associations between anti-αvβ6 autoantibodies and UC-related outcomes were defined using Cox proportional hazards model. Anti-αvβ6 autoantibodies were significantly higher among individuals who developed UC compared with controls up to 10 years before diagnosis in PREDICTS. The anti-αvβ6 autoantibody seropositivity was 12.2% 10 years before diagnosis and increased to 52.4% at the time of diagnosis in subjects who developed UC compared with 2.7% in controls across the 4 time points. Anti-αvβ6 autoantibodies predicted UC development with an area under the curve of at least 0.8 up to 10 years before diagnosis. The presence of anti-αvβ6 autoantibodies in preclinical UC samples was validated in the GEM cohort. Finally, high anti-αvβ6 autoantibodies was associated with a composite of adverse UC outcomes, including hospitalization, disease extension, colectomy, systemic steroid use, and/or escalation to biologic therapy in recently diagnosed UC. Anti-integrin αvβ6 autoantibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes. [Display omitted]